期刊文献+

美索巴莫磷酸钠在大鼠体内的药代动力学研究

Pharmacokinetic features of methocarbamal sodium phosphate in rats
下载PDF
导出
摘要 目的:研究灌胃和肌内注射给予美索巴莫磷酸钠后在大鼠体内的药代动力学特征。方法:应用高效液相色谱法测定大鼠血浆中的美索巴莫浓度,以3P97药代动力学软件拟合药代动力学参数。结果:美索巴莫磷酸钠以128、256和512 mg/kg单次灌胃给药后,主要药代动力学参数t1/2分别为(0.86±0.28)、(1.50±0.47)和(2.74±1.31)h;C_(max)分别为(39.09±11.60)、(58.97±20.22)和(82.62±21.44)μg/ml;AUC_(0-t)分别为(75.00±28.58)、(175.94±94.77)和(350.05±122.99)μg/ml·h。美索巴莫磷酸钠以128、256和512 mg/kg单次肌内注射给药后,主要药代动力学参数t1/2分别为(1.15±0.45)、(1.44±0.59)和(1.95±0.82)h;C_(max)分别为(75.98±18.83)、(117.00±16.51)和(157.85±13.26)μg/ml;AUC_(0-t)分别为(145.36±53.64)、(270.57±109.38)和(467.52±210.05)μg/ml·h。结论:美索巴莫磷酸钠灌胃或肌注给药后在大鼠体内的药代动力学过程符合一级吸收一房室开放模型特点,随剂量的增加,消除半衰期t1/2、峰浓度C_(max)和曲线下面积AUC_(0-t)均有相应的增高趋势。 Objective:To investigate the pharmacokinetic characteristics of methocarbamol sodium phosphate(Me-Na)in rats after intragastric and intramuscular administration.Methods:The rat plasma concentrations of methocarbamol were determined by HPLC.Pharmacokinetic parameters were evaluated by 3P97 software.Results:For intragastric administration of Me-Na at a single doses of 128,256 or 512 mg/kg,the main pharmacokinetic parameters were as follows:t 1/2 was(0.86±0.28),(1.50±0.47)and(2.74±1.31)h,respectively;C max was(39.09±11.60),(58.97±20.22)and(82.62±21.44)μg/ml,respectively;AUC(0-t)was(75.00±28.58),(175.94±94.77)and(350.05±122.99)μg/ml·h,respectively.While Me-Na was intramuscularly injected at a single dose of 128 mg/kg,256 mg/kg,or 512 mg/kg,respectivels,the main pharmacokinetic parameters were as follows:t 1/2 was(1.15±0.45),(1.44±0.59)and(1.95±0.82)h,respectively;C max was(75.98±18.83),(117.00±16.51)and(157.85±13.26)μg/ml,respectively;AUC(0-t)was(145.36±53.64),(270.57±109.38)and(467.52±210.05)(μg/ml)·h,respectively.Conclusions:The characteristics of pharmacokinetic processes of Me-Na in rats after intragastric administration and intramuscular injection are in consistence with one compartment open model.With the increase of the dose,the elimination half-lives t 1/2,the peak concentrations C max and the areas under the curve AUC(0-t)exhibit a tendency to increase correspondingly.
作者 张晓梅 庄俊雪 杨希 庄布军 尚曼 焦建杰 Zhang Xiaomei;Zhuang Junxue;Yang Xi;Zhuang Bujun;Shang Man;Jiao Jianjie(School of Pharmacy,Tianjin Medical University,Tianjin 300070;Department of Pharmacology,Tianjin Medical University,Tianjin 300070)
出处 《天津药学》 2018年第2期1-4,34,共5页 Tianjin Pharmacy
关键词 美索巴莫磷酸钠 高效液相色谱 药代动力学 methocarbamol sodium phosphate HPLC pharmacokinetics
  • 相关文献

参考文献10

二级参考文献102

  • 1陈琳,郭玉璞,任海涛,赵燕环.肌纤维内脂滴增多在炎性肌病中的意义[J].中华神经科杂志,2005,38(4):224-227. 被引量:9
  • 2童英,冯致英,杨永年,沈克中,姚泰,李鹏.溴氰菊酯对家兔脊髓诱发电位的影响[J].中国药理学与毒理学杂志,1989,3(1):57-62. 被引量:1
  • 3文马力,宋文阁.小针刀剥离配合手法松解治疗重型肩周炎疗效观察[J].重庆医学,2006,35(3):251-252. 被引量:4
  • 4毕鸿雁,张巍,沈光丽,吕鹤,姚生,袁云.风湿性多肌痛的骨骼肌病理改变特点[J].中华老年医学杂志,2006,25(11):832-835. 被引量:4
  • 5Gonzalez-Gay MA,Amoli MM,Garcia-Porrua C,et al.Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.Semin Arthritis Rheum,2003,33:38-48.
  • 6Spiera R,Spiera H.Inflammatory diseases in older adults:polymyalgia rheumatica.Geriatrics,2004,59:39-43.
  • 7Duhaut P,Abert MC,Le Page L,et al.Giant cell arteritis and polymyalgia rheumatica:influence of past pregnancies? The GRACG multicenter case control study.Rev Med Interne,2004,25:792-800.
  • 8Gonzalez-Gay MA.Giant cell arteritis and polymyalgia rheumatica:two different but often overlapping conditions.Semin Arthritis Rheum,2004,33:289-293.
  • 9Mandell BF.Polymyalgia rheumatica:clinical presentation is key to diagnosis and treatment.Cleve Clin J Med,2004,71:489-495.
  • 10Bird HA,Esselinckx W,Dison ASJ,et al.An evaluation of criteria for polymyalgia rheumatica.Ann Rheum Dis,1979,38:434-439.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部